Patient Voices Swayed US FDA's Imlygic Review Team
This article was originally published in SRA
Executive Summary
Patient and caregiver testimony during the US Food and Drug Administration's advisory committee review of Amgen Inc.'s Imlygic (talimogene laherparepvec) was a key factor pushing the agency toward full approval of the oncolytic virus therapy for melanoma lesions in the skin and lymph nodes, review documents show.